Xilio Therapeutics
31 hedge funds and large institutions have $13.7M invested in Xilio Therapeutics in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 6 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
3% more funds holding
Funds holding: 30 → 31 (+1)
2% more capital invested
Capital invested by funds: $13.4M → $13.7M (+$299K)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.43% less ownership
Funds ownership: 3.23% → 2.81% (-0.43%)
Top Buyers
Top Sellers
XLO Hedge Fund Activity: Q2 2024 in Review
31 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q2 2024, worth a combined $13.7M — up 2.2% from $13.4M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new XLO positions and 6 closed out — a net gain of 1 holder — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Rock Springs Capital Management, adding an estimated $1.75M. The largest seller was Atlas Venture Life Science Advisors, exiting entirely with an estimated $1.07M sold.
- 31 institutional investors held Xilio Therapeutics (XLO) as of Q2 2024, up from 30 in Q1 2024.
- Funds reported $13.7M of Xilio Therapeutics stock for Q2 2024, up 2.2% quarter-over-quarter.
- 7 funds opened new Xilio Therapeutics positions in Q2 2024 and 6 closed out, a net change of +1 holder.
- The largest Xilio Therapeutics buyer in Q2 2024 was Rock Springs Capital Management, an estimated $1.75M added.
- The largest Xilio Therapeutics seller in Q2 2024 was Atlas Venture Life Science Advisors, an estimated $1.07M sold.
Based on aggregated 13F filings for Q2 2024.